Effect of point-of-care ultrasound on 30-day readmission among adults with type 2 diabetes
Published
April 17, 2026
Paper ID
PAP-000105
Status
Published
DOI
10.65712/tmj.test000363
Advance Services
Abstract
Background: The cost of 30-day readmission to health systems is substantial. Methods: Eligible participants were adults with type 2 diabetes. Results: 30-day readmission occurred in 17% of the intervention group versus 36% of controls. 3541 participants were included (median age 70 years). Conclusion: Future work should test point-of-care ultrasound in a pragmatic multicentre trial.
References
1. Moreau S, Okafor O, et al. Point-of-care ultrasound and post-operative delirium. Crit Care Med. 2015;383(11):190-948.
2. Mueller P, Yilmaz V, et al. High-flow nasal oxygen and emergency department revisits. Eur Heart J. 2020;348(7):29-1550.
3. Rahman Z, Zhang T, et al. A sepsis alert system and ventilator-free days. JAMA. 2014;198(6):483-1417.
4. Costa Y, Ahmed F, et al. An enhanced recovery pathway and 30-day readmission. Lancet. 2023;110(11):457-1306.
5. Ahmed H, Rahman V, et al. Frailty screening and time to diagnosis. N Engl J Med. 2013;82(7):621-1645.
6. Novak I, Ibrahim P, et al. SGLT2 inhibitors and time to diagnosis. Pediatrics. 2014;388(6):663-1537.
Introduction
The cost of 30-day readmission to health systems is substantial. Practice around point-of-care ultrasound varies widely between centres.
Practice around point-of-care ultrasound varies widely between centres. 30-day readmission remains a leading cause of avoidable harm among adults with type 2 diabetes.
30-day readmission remains a leading cause of avoidable harm among adults with type 2 diabetes. Earlier studies of point-of-care ultrasound were small or single-centre.
Materials and Methods
Missing data were handled with multiple imputation. Eligible participants were adults with type 2 diabetes. We conducted a systematic review and meta-analysis across 9 centres between 2015 and 2022.
The primary outcome was 30-day readmission, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity. Eligible participants were adults with type 2 diabetes.
The primary outcome was 30-day readmission, assessed blind to allocation. Missing data were handled with multiple imputation. Eligible participants were adults with type 2 diabetes.
Results
3197 participants were included (median age 60 years). 431 participants were included (median age 70 years). Effects were consistent across prespecified subgroups.
The adjusted odds ratio was 0.38 (95% CI 0.28 to 0.63). 2877 participants were included (median age 37 years). The adjusted odds ratio was 0.68 (95% CI 0.31 to 0.65).
The adjusted odds ratio was 0.80 (95% CI 0.21 to 0.70). Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.90 (95% CI 0.40 to 0.97).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Centre B | 437 | 23 | 35.2 | 0.70 |
| Intervention | 666 | 19 | 9.0 | 0.68 |
| Male | 889 | 15 | 14.5 | 0.56 |
| Control | 602 | 102 | 27.3 | 0.71 |
| Control | 782 | 105 | 27.8 | 0.61 |
Values are n (%) unless stated otherwise.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.

Shown for adults with type 2 diabetes; error bars are 95% confidence intervals.
30-day readmission occurred in 13% of the intervention group versus 19% of controls. 30-day readmission occurred in 10% of the intervention group versus 38% of controls. Serious adverse events were rare and similar between groups.
Discussion
Future work should test point-of-care ultrasound in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
Implementation will depend on staffing, cost and local protocols. Future work should test point-of-care ultrasound in a pragmatic multicentre trial.
Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.
These findings suggest that point-of-care ultrasound is associated with better 30-day readmission in adults with type 2 diabetes. Residual confounding cannot be excluded. Implementation will depend on staffing, cost and local protocols.
Future work should test point-of-care ultrasound in a pragmatic multicentre trial.
Conclusions
Point-of-care ultrasound should be considered for adults with type 2 diabetes to improve 30-day readmission.
Appendices
The statistical analysis plan is in the online supplement.